PSMA PET and MRI in Gynecological Cancers

The investigators will evaluate a novel second-generation low-molecular-weight prostate
specific membrane antigen (PSMA)-based positron emission tomography (PET) agent, 18F-DCFPyL,
to determine the presence or absence of cancer, the accurate distribution of cancer and the
normal biodistribution of PSMA in the abdomen and pelvis on PET imaging.

PSMA, also known as folate hydrolase 1 and glutamate carboxypeptidase II, is an enzyme
associated with prostate cancer but has been also found to be expressed in the tumor
neovasculature of many different types of non-prostate cancer tumors. PSMA-based 18F-DCFPyL
PET demonstrates very high tumor-to-background ratio when studied in other tumors, including
prostate tumors.

MR imaging is a highly sensitive and specific imaging modality that can be used for
gynecologic cancers. MR images can be obtained in conjunction with PSMA PET, adding
additional anatomic and multi-parametric MRI information without the need for a second
imaging appointment.

Inclusion Criteria for health female controls (Non-dosimetry):

- Women with no suspected gynecological cancer.

- No contraindications for MR or PET imaging.

- Greater than or equal to 18 years of age.

- Scheduled to undergo a hysterectomy and/or salpingo-oophorectomy

Inclusion Criteria (Dosimetry)

- Women with or without suspected gynecological cancer.

- No contraindications for MR or PET imaging.

- Greater than or equal to 18 years of age.

Inclusion Criteria for gynecological cancer patients

- Women with known or suspected gynecological cancer

- No contraindications for MR or PET imaging.

- Greater than or equal to 18 years

- Have had or are scheduled to undergo a hysterectomy and/or salpingo-oophorectomy

Exclusion Criteria:

- Women that are pregnant or breast-feeding.

- Age <18

- Inability to provide informed consent on their own behalf

- Severe kidney dysfunction (GFR <30 mL/min/1.73m2)